40 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
Hepatocellular carcinoma (HCC) studies often require a Child-Pugh class, viral-hepatitis status, and prior local therapy such as TACE. Some records enroll other primary liver tumors. Read the condition field; we do not merge different liver cancers into one recommendation. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (21) · Phase 2 (7) · Phase 1 (6) · Phase 1 / Phase 2 (5) · Phase 3 (1)
Intervention hubs that overlap this snapshot: Nivolumab · Pembrolizumab
This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate.
NCT00034216 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup.
NCT00451022 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
NCT02417740 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).
NCT03572465 · Official ClinicalTrials.gov record · Centre hospitalier de l'Université de Montréal (CHUM)
This is a phase 2 single-arm, open-label clinical trial determining how well it works of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
NCT04472767 · Official ClinicalTrials.gov record · University of California, Irvine
Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion".
NCT04587739 · Official ClinicalTrials.gov record · University Hospital, Lille
Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the how well it works of new therapeutic strategies.
NCT04690972 · Official ClinicalTrials.gov record · Institut National de la Santé Et de la Recherche Médicale, France
This is a monocentric, single blind, treatment, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs.
NCT05828446 · Official ClinicalTrials.gov record · Naik Vietti Violi
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings.
NCT05969860 · Official ClinicalTrials.gov record · Mayo Clinic
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
NCT06066138 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion.
NCT06242470 · Official ClinicalTrials.gov record · MacroGenics
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multi-country, multi-center, watch-and-measure (no experimental treatment required) study of patients with a confirmed diagnosis of hepatobiliary cancer treated with or without a durvalumab-based regimen as part of routine clinical practice or early access program (EAP).
NCT06252753 · Official ClinicalTrials.gov record · AstraZeneca
The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address.
NCT06260943 · Official ClinicalTrials.gov record · University of Miami
This study is designed to assess the how well it works and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).
NCT06330064 · Official ClinicalTrials.gov record · Daiichi Sankyo
The goal of this watch-and-measure (no experimental treatment required) study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure.
NCT06486454 · Official ClinicalTrials.gov record · HistoSonics, Inc.
Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan.
NCT06503146 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
The purpose of the dose escalation part of the study is to characterize the whether it is safe and how hard side effects are to live with of ALN-BCAT as this drug alone and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as this drug alone and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to measure the antitumor activity of ALN-BCAT as this drug alone and in combination with pembrolizumab; to characterize the whether it is safe and how hard side effects are to live with of ALN-BCAT as this drug alone and in combination with pembrolizumab.
NCT06600321 · Official ClinicalTrials.gov record · Alnylam Pharmaceuticals
Non-alcoholic fatty liver disease (NAFLD) is a new condition that has become the most common chronic liver disease in the world and a main cause of liver cirrhosis, liver failure and liver cancer. Obesity and diabetes, conditions that are very common among Veterans are the main risk factors for NAFLD.
NCT06671886 · Official ClinicalTrials.gov record · VA Office of Research and Development
The investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection or ablation(2) to assess the production of CO in patients following liver resection or ablation and correlate these findings to the rate of liver regeneration and liver function.
NCT06681818 · Official ClinicalTrials.gov record · Englewood Hospital and Medical Center
This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT06811116 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)
The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe form, Metabolic dysfunction-associated steatohepatitis (MASH), is high and they are increasingly becoming major causes of cirrhosis, hepatocellular carcinoma (HCC), and the need for liver transplantation. Due to the lack of noticeable symptoms during the early stages, the detection of MASLD is often delayed until the disease has advanced.
NCT06879236 · Official ClinicalTrials.gov record · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
NCT06953089 · Official ClinicalTrials.gov record · DualityBio Inc.
This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength.
NCT07059884 · Official ClinicalTrials.gov record · Alliance for Clinical Trials in Oncology
The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known.
NCT07189624 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
NCT07197554 · Official ClinicalTrials.gov record · SEED Therapeutics, Inc.
This is a Phase 2b, randomly assigned, blinded clinical trial investigating the how well it works and safety of visugromab in combination with nivolumab and Lenvatinib compared to double dummy treatment (placebo) and Lenvatinib in participants with unresectable or metastatic HCC and compensated liver function (Child-Pugh A) after failure of 1L treatment that included an anti-PD-(L)1 compound. The trial consists of 2 Parts: a non-randomly assigned Safety-run-in part (Part 1) and the subsequent randomly assigned part (Part 2) with 2 treatment arms (A and B).
NCT07219459 · Official ClinicalTrials.gov record · CatalYm GmbH
This is a non-treatment, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.
NCT07284121 · Official ClinicalTrials.gov record · Hoffmann-La Roche
This study wants to measure the whether it is safe and how hard side effects are to live with of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
NCT07291076 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
This study wants to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
NCT07430202 · Official ClinicalTrials.gov record · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates reaching 50% and 70%, respectively.
NCT07487662 · Official ClinicalTrials.gov record · Sun Yat-sen University
This study wants to measure the comprehensive therapeutic how well it works and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
NCT07557914 · Official ClinicalTrials.gov record · Haibo Shao
This study is to measure the whether it is safe and how hard side effects are to live with to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor how well it works (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed.
NCT07636785 · Official ClinicalTrials.gov record · VM Discovery, Inc.
This single-center prospective watch-and-measure (no experimental treatment required) cohort study aims to measure the predictive value of peripheral blood-based biomarkers for treatment response in patients with hepatocellular carcinoma (HCC) receiving first-line atezolizumab plus bevacizumab (T+A) therapy. Residual peripheral blood samples obtained during routine clinical testing will be analyzed without additional blood draws.
NCT07734857 · Official ClinicalTrials.gov record · Shanghai Zhongshan Hospital
This proposal describes a non-therapeutic diagnostic clinical trial to estimate the ability of DNP-MRS imaging of hyperpolarized 1-13C-pyruvate uptake and metabolism to predict response following LRT with TACE/TARE/Microwave Ablation or ST in patients with Barcelona Clinic Liver Cancer (BCLC) stage A, B or C HCC. The primary hypothesis is that intratumoral pyruvate, lactate, alanine and carbon dioxide/bicarbonate measured by DNP-MRSI correspond to cellular viability resulting from recurrent or progressive HCC following LRT or ST.
NCT07807475 · Official ClinicalTrials.gov record · Abramson Cancer Center at Penn Medicine
This Vietnam-based watch-and-measure (no experimental treatment required) study examines ecto-nucleotide pyrophosphatase/phosphodiesterase 1/cyclic GMP-AMP synthase (ENPP1/cGAS) protein and stromal fibroblast activation protein (FAP) expression in multiple solid tumor samples using immunohistochemistry (IHC). The study involves no investigational treatments or participant-facing procedures.
NCT07808164 · Official ClinicalTrials.gov record · Tam Anh Research Institute
The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
NCT07817147 · Official ClinicalTrials.gov record · Banner Health
The goal of this clinical trial is to learn how well BGB-B2033 works and how safe it is in people with hepatocellular carcinoma (HCC) who have previously received up to two treatments that included programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) medicines. Researchers will compare BGB-B2033 with either sorafenib or lenvatinib chosen by the study doctor to see which treatment works better and is safer.
NCT07836530 · Official ClinicalTrials.gov record · BeOne Medicines
Alcohol-associated liver disease (ALD) is a major cause of mortality from advanced liver disease, accounting for 47.9% of cirrhosis-related deaths and 30% of hepatocellular carcinoma-related deaths annually. In China, both per capita alcohol consumption and the prevalence of ALD (approximately 5.15%) are on the rise, making ALD an increasingly significant public health burden.
NCT07897981 · Official ClinicalTrials.gov record · Li Lab,MD
In this randomly assigned study it should be investigated, whether and to what extent standard TACE treatment combined with additional stereotactic body radiotherapy (SBRT) leads to improved outcomes for patients with HCC when used as a bridging therapy prior to liver transplantation.
NCT07924943 · Official ClinicalTrials.gov record · AIO-Studien-gGmbH
This prospective watch-and-measure (no experimental treatment required) cohort study will compare the survival outcomes of anatomic liver resection (ALR) versus nonanatomic liver resection (NALR) in patients with initially unresectable hepatocellular carcinoma (HCC) who become eligible for resection following immune checkpoint inhibitor (ICI)-based conversion therapy. Emerging evidence suggests that surgical resection may provide a survival benefit for selected patients with initially unresectable HCC after conversion therapy; however, the optimal surgical approach for these patients remains unclear.
NCT07927452 · Official ClinicalTrials.gov record · Sun Yat-sen University
This hub lists 40 recruiting Liver cancer studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “hepatocellular carcinoma” at https://clinicaltrials.gov/search?cond=hepatocellular%20carcinoma.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Los Angeles, California; New York, New York; Taipei, Taiwan; Houston, Texas; Pittsburgh, Pennsylvania. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.
Trials testing new drugs, antibody therapies, surgery timing, and radiation approaches.
Hormone therapy, PSMA-targeted drugs, and active-surveillance studies.
Immunotherapy, targeted pills for EGFR/ALK, and early-detection studies.
Immunotherapy, targeted drugs, and surgery-timing studies for colon and rectal cancer.
Chemotherapy combinations, KRAS-targeted drugs, and earlier-detection studies.
Checkpoint drugs, TIL therapy, and adjuvant studies after surgery.